Evidence map›Paper›PMID 34024402›Full record

ReviewClinics in chest medicine2021

Rethinking Idiopathic Pulmonary Fibrosis.

Justin M Oldham, Carlo Vancheri

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in chest medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Justin M OldhamDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, 4150 V Street Suite 3400, Sacramento, CA 95817, USA. Electronic address: joldham@ucdavis.edu.
Carlo VancheriDepartment of Clinical and Experimental Medicine, University of Catania, Regional Referral Center for Rare Lung Diseases, University-Hospital "Policlinico -Vittorio Emanuele", Catania, Italy.
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITUniversity of California, Davis · US

Funding

Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung diseaseR03HL157895 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OLDHAM, JUSTIN M · 2021 to 2022
$157k
NHLBI NIH HHS K23 HL138190NHLBI NIH HHS R03 HL157895
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating disease for patients and their loved ones. Since initial efforts to characterize this disease in the 1960s, understanding of IPF has evolved considerably. Such evolution has continually challenged prior diagnostic and treatment paradigms, ushering in an era of higher confidence diagnoses with less invasive procedures and more effective treatments. This review details how research and clinical experience over the past half century have led to a rethinking of IPF. Here, the evolution in understanding of IPF pathogenesis, diagnostic evaluation and treatment approach is discussed.

Indexed as

Idiopathic Pulmonary FibrosisHumansIdiopathic interstitial pneumoniaIdiopathic pulmonary fibrosisInterstitial lung diseaseUsual interstitial pneumonia

Identifiers

PMID34024402
PMCPMC9075032
OpenAlexW3164509546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.